<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376882</url>
  </required_header>
  <id_info>
    <org_study_id>24G4</org_study_id>
    <nct_id>NCT01376882</nct_id>
  </id_info>
  <brief_title>Cognitive and Cerebral Blood Flow Effects of 2-week Caffeine Abstinence or Maintenance</brief_title>
  <official_title>Behavioural and Cerebral Haemodynamic Effects of Caffeine Withdrawal and Caffeine Administration Following 2-week Maintenance or Abstinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northumbria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northumbria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of 2 weeks caffeine abstinence as
      compared to 2 weeks caffeine maintenance (300mg per day)on cognition and mood. Cerebral blood
      flow effects will also be assessed in a subset of participants. The role of caffeine
      abstinence/maintenance in the acute effects of caffeine will also be explored.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current randomised, placebo-controlled, double-blind, parallel groups study aims to
      explore the behavioural effects of 2-weeks caffeine abstinence as well as establishing the
      role of abstinence in the effects of caffeine administration by administering caffeine or
      placebo to those in a state of chronic and acute abstinence. This research also aims to
      explore, in a subset of participants, the cerebral blood flow effects of caffeine abstinence
      and caffeine administration using Near Infrared Spectroscopy (NIRS). Cerebral blood flow will
      be measured both at rest and during performance of cognitive tasks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive performance</measure>
    <time_frame>2 weeks</time_frame>
    <description>Performance is assessed using COMPASS (Computerised Mental Performance Assessment System), which presents a battery of standard cognitive tasks assessing aspects of attention and memory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>2 weeks</time_frame>
    <description>Mood will be evaluated using Visual Analogue Scales administered using COMPASS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral haemodynamic</measure>
    <time_frame>2 weeks</time_frame>
    <description>Cerebral blood flow will be measured in a subset of participants using Near Infrared Spectroscopy (NIRS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>2 weeks</time_frame>
    <description>Quality of sleep will be measured using the Pitsburgh Sleep Quality Index (PSQI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine withdrawal</measure>
    <time_frame>2 weeks</time_frame>
    <description>Symptoms of caffeine withdrawal will be measured using a Subjective and Somatic State Questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Cognitive Function</condition>
  <condition>Mood</condition>
  <condition>Cerebral Haemodynamics</condition>
  <condition>Caffeine Withdrawal</condition>
  <arm_group>
    <arm_group_label>Acute withdrawal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic intervention 100 mg caffeine capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute caffeine-independent of withdrawal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic abstinence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute caffeine-in state of withdrawal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic intervention of 100 mg caffeine capsule 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.</description>
    <arm_group_label>Chronic abstinence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Caffeine and Placebo</intervention_name>
    <description>100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.</description>
    <arm_group_label>Acute withdrawal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo and Caffeine</intervention_name>
    <description>Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.</description>
    <arm_group_label>Acute caffeine-independent of withdrawal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.</description>
    <arm_group_label>Acute caffeine-in state of withdrawal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/Female

          -  18 - 40 years

          -  Healthy

          -  Consume â‰¥ 150 mg caffeine daily

          -  No herbal supplements/prescription medications (excl. contraceptive pill)

          -  Non smoker

          -  Native English speaker

        Exclusion Criteria:

          -  Diagnosis of any significant medical condition or disorder

          -  Any known allergy or hypersensitivity to food.

          -  BMI &gt;29.9 or &lt;18.5

          -  Blood pressure &gt;139/89
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Crystal Haskell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northumbria University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brain, Performance and Nutrition Research Centre, Northumbria University</name>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <state>Tyne and Wear</state>
        <zip>NE1 8ST</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.nutrition-neuroscience.org</url>
    <description>Brain, Performance and Nutrition Research Centre, Northumbria University</description>
  </link>
  <link>
    <url>http://www.cognitivetesting.co.uk</url>
    <description>COMPASS software</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>March 28, 2013</last_update_submitted>
  <last_update_submitted_qc>March 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northumbria University</investigator_affiliation>
    <investigator_full_name>Crystal Haskell</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Caffeine</keyword>
  <keyword>Withdrawal</keyword>
  <keyword>Cognitive function</keyword>
  <keyword>Mood</keyword>
  <keyword>Cerebral haemodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

